Cedars-Sinai Medical Center Department of Neurology, 127 S. San Vicente Blvd, A6600, Los Angeles, CA, 90048, USA.
Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave. U10 Mellen Center, Cleveland, OH, 44106, USA.
Curr Neurol Neurosci Rep. 2022 Oct;22(10):675-688. doi: 10.1007/s11910-022-01227-1. Epub 2022 Oct 21.
For many patients, the multiple sclerosis (MS) diagnostic process can be lengthy, costly, and fraught with error. Recent research aims to address the unmet need for an accurate and simple diagnostic process through discovery of novel diagnostic biomarkers. This review summarizes recent studies on MS diagnostic fluid biomarkers, with a focus on blood biomarkers, and includes discussion of technical limitations and practical applicability.
This line of research is in its early days. Accurate and easily obtainable biomarkers for MS have not yet been identified and validated, but several approaches to uncover them are underway. Continue efforts to define laboratory diagnostic biomarkers are likely to play an increasingly important role in defining MS at the earliest stages, leading to better long-term clinical outcomes.
对于许多患者来说，多发性硬化症（MS）的诊断过程可能既漫长又昂贵，而且容易出错。最近的研究旨在通过发现新的诊断生物标志物来满足对准确而简单的诊断过程的需求。这篇综述总结了多发性硬化症诊断液生物标志物的最新研究，重点是血液生物标志物，并讨论了技术局限性和实际适用性。
这一研究领域还处于早期阶段。尚未确定和验证用于 MS 的准确且易于获取的生物标志物，但正在采用几种方法来发现它们。继续努力定义实验室诊断生物标志物可能在早期阶段对定义 MS 发挥越来越重要的作用，从而带来更好的长期临床结局。
